ArticleThe Journal of clinical endocrinology and metabolism2011

The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

Ruixin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.